Table 4.
Summary of currently enrolling DMG/DIPG trials that require a biopsy for enrollment.
| NCT Number | Study Title | Description | N | Start Date (Month-Yr) | Completion Date (Month-Yr) | Location |
|---|---|---|---|---|---|---|
| NCT04099797 | C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B) | Patients with GD2-expressing newly diagnosed DMG will be treated with intracerebroventricular administration of G7R-GD2 CAR T cells followed by intravenous administration | 34 | February-20 | February-24 | US |
| NCT04196413 | GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas(DIPG) & Spinal Diffuse Midline Glioma(DMG) | Patients with H3K27M-mutant DIPG will be treated with autologous T-cells transduced with retroviral vector expressing GD2-chimeric antigen), i.e. a type of CAR-T therapy | 54 | June-20 | July-43 | US |
| NCT04655404 | A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion | Patients with NTRK fusion alterations are treated with larotrectinib (Tkr inhibitor) | 15 | April-21 | December-25 | US |
| NCT04732065 | ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors | Patients with DMG H3K27 altered who have had prior radiation will receive DRD2 antagonist/ClpP agonist ONC206 | 256 | August-21 | December-27 | US |
| NCT04749641 | Neoantigen Vaccine Therapy Against H3.3-K27M Diffuse Intrinsic Pontine Glioma | Patients with the H3.3-K27M variant are treated with vaccine | 30 | March-21 | December-24 | China |
| NCT04837547 | PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy | Patients are treated with tumor-specific ex vivo expanded autologous lymphocyte transfer | 24 | September-21 | September-24 | US |
| NCT04943848 | rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG | (biopsy required for DMG, not typical DIPG, to confirm histone methylation) Patients are treated with neoantigen heat shock protein vaccine and balsitilimab (anti-PD1) and/or zalifrelimab (anti CTLA4) | 36 | January-22 | March-24 | US |
| NCT05278208 | Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors | Patients with biopsy proven DIPG, with expression of SST2A and uptake on DOTATE PET will receive Lutetium 177 dotate | 65 | November-22 | November-24 | US |
| NCT05478837 | Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients With H3.3K27M-Mutated Glioma | Newly diagnosed patients with H3.3K27M mutant DMG and HLA-A*0201 will be treated with KIND T cells (autologous anti-H3.3K27M TCR-expressing T cells) | 12 | July-23 | August-29 | US |
| NCT05544526 | CAR T Cells to Target GD2 for DMG | Patients with H3K27M mutant DMG will receive CAR T therapy with GD2 CAR T cells | 12 | August-23 | December-39 | UK |
| NCT05717699 | Oncolytic Virus Ad-TD-nsIL12 for Progressive Pediatric Diffuse Intrinsic Pontine Glioma | Patients with progressive DIPG are enrolled and undergo biopsy with concurrent placement of Ommaya reservoir through the biopsy channel. After surgery, they are treated through the reservoir with Ad-TD-nsIL12 (a novel oncolytic virus) which is delivered into the tumor. | 18 | January-23 | January-28 | China |
| NCT05717712 | Oncolytic Virus Ad-TD-nsIL12 for Primary Pediatric Diffuse Intrinsic Pontine Glioma | Patients with newly diagnosed radiographic DIPG are enrolled and undergo biopsy with concurrent placement of Ommaya reservoir through the biopsy channel. After surgery, they are treated through the reservoir with Ad-TD-nsIL12 (a novel oncolytic virus) which is delivered into the tumor. | 18 | January-23 | January-28 | China |
| NCT06305910 | CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults | Patients with H3K27M altered DIPG/DMG will be given GBM6-AD vaccine and CD200AR-L (CD200 activation receptor ligand) | 24 | March-24 | January-27 | US |